Wednesday, May 22, 2019
News
NEWS HOME
»
PRESS RELEASES

French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
  SocialTwist Tell-a-Friend  
   


Date: 17-04-2019 11:27AM
Source: CellVax
Category: General, Science & Research, Healthcare & Biotechnology, Medical Devices, Pharmaceutical
Location: Maison-Alfort, France

Business Wire India

  • CellVax announces it has signed strategic partnership with 2 large Chinese pharmaceutical companies: Medtech OSMUNDA, a worldwide leading clinical trial CRO and service provider of medical devices, and big pharmaceutical actor: Guangzhou General Pharmaceutical Research Institute.
  • CellVax is now able to propose to its European customers new standards for preclinical and clinical studies, with large nonrodent animals models
  • Qualifying strategy to meet international standards of scientific quality control
  • Public & private financing underway to support CellVax’s strong growth.

Thanks to this strategic partnership, CellVax can now respond to the strong demand for optimal selection of models that represent the human disease best and is ableto offer preclinical studies in large nonrodent species as well as diversified preclinical models or clinical trials.
Large animal models are essential for the development of novel therapeutics for Cancer and Osteoarthritis (OA) fields, the two research specialties of CellVax. Through this partnership, the company has achieved a significant progress in its capacity to provide wide range of animal models for these diseases.
From now on, CellVax offers to fully realize high value-added projects in China and France / Europe, including product registrations in China for European clients, or a better understanding of European markets for Chinese clients.

Quicker funding to support the growth and to finance quality and R&D resources, innovation driver for CellVax
Since February 2019, CellVax has made a strong commitment to enhance the quality of its preclinical studies. Currently, one large GLP toxicology and Bio-distribution study is ongoing at CellVax.
By the end of 2019, CellVax will be able to perform a full range of GLP-compliant preclinical studies in large and small animals for the development of drugs, vaccines and medical devices.

Furthermore, CellVax is fully invested in numerous large-scale European collaborative research programs such as Eureka, FP-7, and Horizon 2020, as well as in the search for new ways of private / public financing in order to continually enhance its R&D capability and to increase its visibility worldwide.

About CellVax – www.cellvax-pharma.com
Founded in 2001, Cellvax is a preclinical Contract Research Organization (CRO) which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis fields. In addition to preclinical studies, CellVax provides high quality consulting services in order to optimize the discovery process of candidate compounds.



CONTACTS :

CELLVAX
Dr. Mingxing WEI, CEO
+33 (0) 671434751 (France) +86 182 271 08395 (China)
contact@cellvax-pharma.com

FIN’EXTENSO
Press Relations
Isabelle Aprile
+33 1 39 97 61 22
i.aprile@finextenso.fr

More Press Releases

ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries

FaceCake to Showcase Entire Platform at Goldman Sachs TechNet Conference Asia Pacific 2019

SAIL Awards Hi-Tech Pipes With 'Top Performer Award'

WNS Named a ‘Leader’ and ‘Star Performer’ in Property & Casualty Insurance Business Process Services by Everest Group

Why Investing in Fixed Deposits Is Ideal Given the Volatility of India’s Markets

Freudenberg Strategically and Operationally Successful

Hiranandani Trust School Panvel Launches Hiramont Pre-School

Mumbai IX Offers 100 Gigabit Ethernet Access: Cloudflare Among First Customers

comforte AG Launches New Payments Industry Data Security Solution

Moldova Citizenship-by-Investment Program Completes First Successful Application

Innovative Logic USB IP PortfolioStrengthens RISC-V Ecosystem

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

Herbalife Nutrition Celebrates 20 Years of Success in India With the Unveiling of H24

GIA India Organised a GemKids Programme in New Delhi

NRI FT India and Digital Asset to Deliver DAML Driven Applications to Capital Markets

Analogix Introduces Its VirtualLink™ Reference Design for High-Performance Gaming Notebooks

Gupta Agarwal Foundation Donates $5 Million to Fund Heart Health Research and Education

CNIM to Optimize Renewable Heat Production for Nantes District Heating

Rubicon Capital Advisors Strengthens its Global Presence through the Formation of a Dedicated Investor Coverage Group and the Opening of a New Office in Seoul, South Korea

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Admission to IP University law courses t...
Sena chief attends NDA dinner...
PM meets Council of Ministers, says LS p...
Mumbai Congress concerned about EVMs saf...
Bastar: 14-day march demanding revival o...
SC dismisses plea challenging appointmen...
More...    
 
 Top Stories
Opposition raising EVM issue unnece... 
Indian educational institutions sho... 
Government may mull over M&As to re... 
Trump nominates Barbara Barrett as ... 
Manali-Keylong road opens for vehic... 
Fake coin minting rackets run rampa... 
No wrong transportation of EVMs: Po... 
Hyundai launches connected compact ...